Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Immunotherapy revisited

Immunotherapy revisited editorial memo (2021) 14:127–128 https://doi.org/10.1007/s12254-021-00711-7 Thorsten Füreder Accepted: 12 April 2021 © Springer-Verlag GmbH Austria, part of Springer Nature 2021 Immunotherapy has revolutionized cancer treatment the immune microenvironment by IDO inhibitors during the last few years. Impressive long-term and discuss recent developments on intratumoral survival rates (beyond 5 years) even in deadly dis- immunotherapy by STING agonists [1]. eases such as metastatic lung cancer or malignant Immunotherapy, however, does not on only com- melanoma were achieved by checkpoint inhibitor prise T-cell and immune microenvironment targeted (CPI) therapy. agents, but also adoptive T cell therapy utilizing en- For melanoma patients a 5-year overall survival gineered chimeric antigen receptors (CAR). Positive (OS) rate of 52% was reported upon administration clinical trials in heavily pretreated patients suffer- of dual CPI therapy with ipilimumab plus nivolumab ing from B-cell malignancies led to the approval of [4]. Despite promising outcomes in this setting, it is CAR-T cell therapy both in the US and in Europe. evident that a considerable number of patients do Long-termdata fromthe ZUMA-1 study, for instance, not benefit from this approach and novel immuno- showed durable responses and a median overall sur- oncological concepts beyond established/approved vival (OS) of 25.2 months http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Loading next page...
 
/lp/springer-journals/immunotherapy-revisited-AL7pRXBYze
Publisher
Springer Journals
Copyright
2021 Springer-Verlag GmbH Austria, part of Springer Nature
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-021-00711-7
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2021) 14:127–128 https://doi.org/10.1007/s12254-021-00711-7 Thorsten Füreder Accepted: 12 April 2021 © Springer-Verlag GmbH Austria, part of Springer Nature 2021 Immunotherapy has revolutionized cancer treatment the immune microenvironment by IDO inhibitors during the last few years. Impressive long-term and discuss recent developments on intratumoral survival rates (beyond 5 years) even in deadly dis- immunotherapy by STING agonists [1]. eases such as metastatic lung cancer or malignant Immunotherapy, however, does not on only com- melanoma were achieved by checkpoint inhibitor prise T-cell and immune microenvironment targeted (CPI) therapy. agents, but also adoptive T cell therapy utilizing en- For melanoma patients a 5-year overall survival gineered chimeric antigen receptors (CAR). Positive (OS) rate of 52% was reported upon administration clinical trials in heavily pretreated patients suffer- of dual CPI therapy with ipilimumab plus nivolumab ing from B-cell malignancies led to the approval of [4]. Despite promising outcomes in this setting, it is CAR-T cell therapy both in the US and in Europe. evident that a considerable number of patients do Long-termdata fromthe ZUMA-1 study, for instance, not benefit from this approach and novel immuno- showed durable responses and a median overall sur- oncological concepts beyond established/approved vival (OS) of 25.2 months

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Jun 1, 2021

Keywords: oncology; medicine/public health, general

References